Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenchone SCHEMBL527930 | 0.86 | MEN1 (0.38) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| Fenchone SCHEMBL856607 | 0.86 | MEN1 (0.38) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| (-)-Fenchone SCHEMBL7997210 | 0.86 | MEN1 (0.38) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| Fenchone SCHEMBL15047583 | 0.86 | MEN1 (0.38) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| (L)-Fenchone SCHEMBL18221219 | 0.86 | MEN1 (0.38) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| (+)-Fenchone SCHEMBL856608 | 0.86 | MEN1 (0.38) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL4140998 | 0.74 | MAPT (0.32) | MAPT | |
| SCHEMBL19388309 | 0.73 | TSHR (0.35) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL6623292 | 0.70 | KMT2A (0.41) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL11349549 | 0.65 | MEN1 (0.32) | MAPTLMNAMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2022-05-17 | — | — | US | disclosed |
| US-20200246406-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20160000722-A1 | DOSAGE FORM FOR CINEOLE | MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT MBH (DE) | 2016-01-07 | — | — | US | disclosed |
| CN-105110442-A | Treatment agent for removing methanol, normal butanol and isobutanol in amino resin workshop waste water | LI HAILAN | 2015-12-02 | — | — | CN | disclosed |
| US-3967629-A | Bicyclic fragrance materials and processes therefor | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246406-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | MAPT 94/4885LMNA 4008/4885MEN1 3386/4885 |
| US-11331358-B2 | Pharmaceutical composition and method of manufacturing | CNR2, CNR1, CYP3A5 | MAPT 94/4885LMNA 4008/4885MEN1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.